Screener
ImmunityBio, Inc. IBRX CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Investing activities: | ||
| Purchases of marketable debt securities, available-for-sale | (139,093) | (100) |
| Proceeds from maturities of marketable debt securities, available-for-sale | 79,382 | 5,350 |
| Proceeds from sales of marketable debt securities, available-for-sale | 39,848 | — |
| Cash paid for other equity securities | (10,000) | — |
| Purchases of property, plant and equipment | (1,776) | (1,121) |
| Software development costs | (11) | — |
| Net cash (used in) provided by investing activities | (31,650) | 4,129 |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s capex?
- ImmunityBio, Inc. (IBRX) reported capex of $1.78M in Q1 2026.
- How has ImmunityBio, Inc.'s capex changed year-over-year?
- ImmunityBio, Inc.'s capex increased by 58.4% year-over-year, from $1.12M to $1.78M.
- What is the long-term trend for ImmunityBio, Inc.'s capex?
- Over 4 years (2021 to 2025), ImmunityBio, Inc.'s capex has grown at a -41.8% compound annual growth rate (CAGR), from $33.56M to $3.85M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about ImmunityBio, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude